Searched for
RISDIPLAM
Ministries split on drug data exclusivityGovernment ministries are in talks over drug data protection rules. This issue involves domestic drug makers, global pharma giants, and pat...- Roche Vs Natco: Supreme Court clears decks for launch of Natco Pharma's Risdiplam generic in IndiaThe Supreme Court has allowed Natco Pharma to launch its generic version of the spinal muscular atrophy drug Risdiplam in India, dismissing...
- Roche moves SC against Natco’s launch of generic Risdiplam in IndiaF. Hoffmann-La Roche AG has approached the Supreme Court. This follows a Delhi High Court decision permitting Natco Pharma to introduce a g...
- Natco wins patent battle to launch generic 'Risdiplam'A Delhi High Court ruling favors Natco Pharma against Roche's rare disease drug. Natco can now launch generic risdiplam, used for spinal mu...
- Delhi HC allows Natco Pharma to launch risdiplam, rejects Roche pleaThe Delhi High Court has permitted Natco Pharma to launch its affordable generic version of risdiplam, a crucial drug for spinal muscular a...
- More patients can access key drugs after GST rate cutsRecent GST rate cuts on critical medicines are set to significantly reduce costs for treatments of conditions like multiple myeloma, lung c...
- Crucial drugs to be more affordable after GST cutThe government has significantly reduced GST rates on 41 highly priced medicines, including those for cancer, rare diseases, and heart cond...
- Zydus Life's plans for cancer biosimilar hit a legal hurdleThe Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a patent infrin...
- Roche made over 100 times the cost of a medicine that it sold in India, calculations show; company defends itselfA recent report in The Times of India reveals that Roche may have profited immensely from risdiplam, a drug for spinal muscular atrophy (SM...
- Natco to sell rare spinal disease drug Risdiplam for ₹15,900Each bottle of Risdiplam lasts around 12 days and that will take the cost to roughly ₹30,000 per month for the patient. Sources said Roche ...
- Delhi HC asks Natco Pharma to pause Risdiplam launch amid patent disputeThe Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the paten...
- Delhi HC rejects Roche's plea to block Natco Pharma on Risdiplam patentThe Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy drug, citing pu...
- SC stays order asking Centre to procure drugs for patient with rare disorderThe Supreme Court has temporarily stayed a Kerala High Court order directing the Centre to provide additional funds for a patient's expensi...
- Budget 2025: 'Customs waiver on life-saving drugs won't benefit most patients'Despite the import duty waiver on life-saving drugs for rare diseases announced in the union budget, patients might not benefit due to high...
- Health groups raise concerns over patents for rare disease drugsHealth groups and patient advocates are raising concerns over patent monopolies on rare disease drugs in India. They argue that these monop...
- Could a Rs 72 lakh drug cost just Rs 3,000? A 24-year-old's courtroom revelationA 24-year-old SMA patient in Kerala High Court revealed that Risdiplam, a crucial SMA drug, could be locally produced for Rs 3,000 annually...
- GST exemption on medicines for rare diseases is unlikely to provide any relief to those in need: Health activistsThe recent GST exemption on medicines for rare diseases in India is unlikely to help many patients as the drugs are still too expensive, sa...
- Scrap taxes on drug import for spinal muscular atrophy, Stalin tells CentreFor children affected by SPA, gene-therapy has to be ideally given before the child reaches two years of age and this therapy costs over Rs...
- ‘Compassionate use’ means life for a fortunate fewDrugs under clinical trials in other countries can be brought to India to treat life-threatening diseases, but prohibitive cost remains a w...
- Mothers’ struggle behind nod for ‘compassionate use’ drugsWhile the mothers waited for guidelines, seven of the 34 children chosen for compassionate use of the new drug, Risdiplam, passed away. “It...
Load More
